Introduction: The strains of Pseudomonas aeruginosa are known as an opportunistic pathogen that can cause infections in humans and animals. Metallo-β-lactamases (MBLs) are the most significant factors of resistance to carbapenem antibiotics in these bacteria. This study was designed to identify the MBLs producing P. aeruginosa isolates in three hospitals of Tehran, Iran. Methods: Tota...

BACKGROUND Several generic imipenem/cilastatin formulations have been approved by Thai FDA and a generic imipenem/cilastatin (Yungjin) has been available in SirirajHospital since 2007. Since imipenem/cilastatin is usually given to the patients with serious hospital-acquired infections, the generic imipenem/cilastatin must be therapeutically equivalent to the original imipenem/cilastatin. The ob...

INTRODUCTION The emergence and rapid spread of blaIMP and blaVIM metallo-beta-lactamase (MBL) producing Gram-negative bacteria causing nosocomial infections are of concern worldwide due to limited treatment options. METHODOLOGY A total of 179 nonreplicate, consecutive, carbapenem resistant Pseudomonas aeruginosa (61), Acinetobacter baumannii (116), Acinetobacter lwoffii (1) and Pseudomonas st...

Background: The frequent use of broad-spectrum antibiotics in ICU leads to increased rates antimicrobial resistance and occurrence multidrug-resistant (MDR) micro-organisms. aim this study was evaluate the pattern colistin susceptibility among bacterial isolates from patients. Method: It is a prospective with 70 nonrepetitive samples. clinical data obtained department records. gram-negative wer...

Three carbapenem-resistant Acinetobacter baumannii isolates were collected at a hospital in Buenos Aires, Argentina. Isoelectric focusing revealed multiple beta-lactamases, with two of the isolates showing identical profiles. A pI 6.9 carbapenemase with a molecular weight of 30 kDa was purified from one of these two isolates. The enzyme was predominantly a penicillinase, with its highest Vmax f...

The aim was to explore the antimicrobial activity of a synthetic peptide (AMP38) and its synergy with imipenem against imipenem-resistant Pseudomonas aeruginosa. The main mechanism of imipenem resistance is the loss or alteration of protein OprD. Time-kill and minimal biofilm eradication concentration (MBEC) determinations were carried out by using clinical imipenem-resistant strains. AMP38 was...

Imipenem is renally metabolized to the stable open-lactam metabolite by a dipeptidase, dehydropeptidase I, located at the lumenal surface of the proximal tubular cells. In humans the degree of hydrolysis shows marked intersubject variability but minimal intrasubject variability. In healthy subjects the urinary recovery of unchanged imipenem ranged from 5.5% to 42.5% of the dose. Cilastatin inhi...